BioWorld

Nov. 21, 2008

FDA Experts Give Thumbs Down to Arpida, Targanta Antibiotics

COLLEGE PARK, Md. - Federal advisers Thursday said Arpida AG failed to show in clinical trials that its experimental antibiotic iclaprim was safe and effective for treating patients with complicated skin and skin structure infections (cSSSIs). (BioWorld Today) Read More

Amgen,Takeda Halt Enrollment in Phase III Trial of Motesanib

Infinity to Get $75M Investment, $50M Credit Line from Purdue

Germany Building Supercluster for Tumor Stem Cell Research

Awaiting Phase II Osteoporosis Data, Radius Adds Another $15M

More Patients Needed in Pivotal Defibrotide Study; Gentium Falls

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...